# Her2-BATS and Pembrolizumab in Metastatic Breast Cancer

> **NCT03272334** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Virginia** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** HER2 BATs with Pembrolizumab

## Key facts

- **NCT ID:** NCT03272334
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-29
- **Primary completion:** 2024-11-30
- **Final completion:** 2031-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03272334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03272334, "Her2-BATS and Pembrolizumab in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03272334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*